Kaposi's Sarcoma-Associated Herpesvirus (KSHV) is the etiological agent of primary effusion lymphoma, a subset of multicentric Castleman's disease, and Kaposi's sarcoma, the most common malignancy in HIV/AIDS patients. KSHV ORF45, an immediate-early gene and tegument protein, activates the cellular kinase RSK, which is essential for optimal lytic gene expression and progeny virion production. The precise role(s) of ORF45-induced RSK activation that contribute to efficient KSHV lytic replication remain to be determined. The long-term goal is to elucidate the mechanism(s) by which KSHV facilitates efficient viral gene expression and productive viral replication by appropriating the host cellular machinery, and how this contributes to KSHV pathogenesis. The immediate objective is to define the roles of ORF45-activated RSK throughout KSHV lytic replication, including contributions of ORF45/RSK substrates to viral epigenomic modifications, transcription and translation. The central hypothesis is that KSHV ORF45-activated RSK alters the activities of several diverse substrates during KSHV lytic replication, resulting in the regulation of epigenomic modifications, transcription and translation. This hypothesis was formulated upon reviewing the primary literature and preliminary data produced by the applicant. The rationale that underlies the proposed research is that it will allow for hypothesis-driven approaches to reveal a mechanistic explanation for the apparent regulation of epigenomic modifications and viral/cellular gene expression by KSHV. The central hypothesis will be tested by pursuing the following specific aims: 1) Determine the roles of KSHV ORF45-activated RSK in the regulation of histone modifications and the consequences on viral and cellular transcription;and 2) Characterize the effects of ORF45-induced RSK activation on viral and cellular translation. To achieve these aims, a system for efficient and inducible KSHV lytic reactivation will be employed. For the first aim, chromatin immunoprecipitation and next-generation sequencing will be used to accurately measure the effect(s) of both KSHV lytic replication and ORF45 activation of RSK on transcriptional regulation.
The second aim will make use of various approaches, including an innovative ribosome profiling technique, to elucidate the functional significance of ORF45- activated RSK with regard to translational control. The expected contributions of the proposed research are to corroborate roles for ORF45-activated RSK in critical regulatory processes during KSHV lytic replication. These contributions will be significant because they will further the understanding of KSHV-induced dysregulation of the host cell signaling pathways, which may be useful in the development of novel treatments for KSHV-related diseases.

Public Health Relevance

The proposed research is relevant to public health, since KSHV is the etiological agent of three human cancers. KSHV seroprevalence is especially high in certain regions of Africa, and AIDS patients or otherwise immunosuppressed individuals are at a particularly high risk of developing KSHV-related diseases. This project is relevant to the mission of the National Cancer Institute because the mechanisms of KSHV pathogenesis are not well understood. The experiments proposed herein will indubitably shed light on some of these mechanisms, and may lead to the development of novel therapeutic options to treat or prevent these cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
1F31CA183250-01
Application #
8649176
Study Section
Special Emphasis Panel (ZRG1-AARR-C (22))
Program Officer
Korczak, Jeannette F
Project Start
2014-01-06
Project End
2016-01-05
Budget Start
2014-01-06
Budget End
2015-01-05
Support Year
1
Fiscal Year
2014
Total Cost
$34,987
Indirect Cost
Name
Florida State University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
790877419
City
Tallahassee
State
FL
Country
United States
Zip Code
32306